Moreover, erythropoietin exerts effects on iron metabolism, by inducing heme synthesis (Camaschella et al., 2016), and promotes mitochondrial biogenesis and oxidative respiration (Carraway et al., 2010; Plenge et al., 2012), further favoring it as a candidate therapy for FRDA. This evidence concerns the gene EPO and Friedreich ataxia.